Worldwide Clinical Trials has entered a strategic collaboration with medical genetics company InVitae to expedite clinical trials for rare disease patients.

Under the collaboration, Worldwide will leverage Invitae’s Explorer tool, which is part of its real-world data platform that offers access to combined genetic testing results.

With the latest development, Worldwide will become the first contract research organisation (CRO) to use the Explorer tool.

The company will also have access to data insights based on demographics, geography, prevalence, incidence and epidemiology for patients with rare diseases, under this deal. 

With this combined data, Worldwide will be able to recruit participants rapidly and locate the best trial locations to aid its sponsors find new and potentially life-saving therapies for rare disease patients.

Invitae co-founder and CEO Sean George said: “Our strategic collaboration enables Worldwide to gain valuable insight into the genetic etiology of rare disease to help shape and improve the future of clinical trials. 

“Our cutting-edge tools empower Worldwide with the opportunity to set clinical trial strategies based on specific disease and geographic prevalence to yield the data needed to treat genetic disorders globally.”

Furthermore, through access to combined genetic testing data of Invitae, Worldwide has improved its expertise to tackle the complications of rare disease trials through enhanced visibility of where patients are.

This ultimately aids the CRO in offering essential and meaningful treatments.

Worldwide Clinical Trials president and co-CEO Peter Benton said: “Our unique access to Invitae’s database provides us with superior visibility to an aggregate-level view of patients we otherwise wouldn’t be aware of and enables us to offer advanced clinical trial strategies to our sponsors. 

“This also helps us boost much-needed patient recruitment efforts, expanding our reach and ability to connect the right patients with the right clinical trial opportunities.”